eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2021
vol. 72
 
Share:
Share:
more
 
 
Original paper

Pulmonary vascular alterations in explanted lung after transplantation

Funda Demirag
1
,
Alkin Yazicioglu
2
,
Sinan Turkkan
2
,
Omac Tufekcioglu
3
,
Erdal Yekeler
2

1.
Department of Pathology, University of Health Sciences, Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey
2.
Department of Thoracic Surgery and Lung Transplantation, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
3.
Department of Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
Pol J Pathol 2021; 72 (2): 130-139
Online publish date: 2021/09/30
Article file
- 04-PJP-01998.pdf  [4.14 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Interstitial lung diseases, chronic obstructive lung disease (COPD), bronchiectasia, Kartegener syndrome, and α-1 thyripsin deficiency are chronic progressive diseases, which bring about worsening of the respiratory condition leading to death. These diseases are resulting end-stage pulmonary diseases. Patients with end-stage pulmonary diseases are prone to developing pulmonary hypertension [1]. The extension of fibrosis and reduction of alveoli are leading causes of vascular changes and pulmonary hypertension. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis, Langerhans cell histiocytosis and obliterative bronchiolitis were investigated previously [2, 3, 4]. However, the correlation between histopathologic pulmonary vascular features and pulmonary hypertension in end-stage pulmonary diseases is not available. Lung transplantation is an acceptable treatment for end-stage pulmonary diseases, which provides longer survival time and life quality. The explanted lung is the most important source for histopathological investigation of end-stage pulmonary diseases. Therefore we designed a retrospective study on explanted specimens. The objectives of the study were as follows: (1) to evaluate pulmonary vascular changes underlying vascular remodeling in end-stage pulmonary diseases (2) to correlate pulmonary hypertension with vascular changes.

Materials and methods

Patients

The Medical Expertise Training Committee has reviewed and approved this study, and all the patients signed an informed consent form. This was a retrospective study of 57 patients who underwent single and double lung transplantation in our center from December 2013 to January 2019. Age, gender, transplantation indication and type of transplantation were retrieved. The transplantation indication of our cases was divided into three groups as emphysematous, fibrotic and suppurative.

Pathological examination of explanted lungs

All explanted lungs were fixed with 10% buffered formalin. For each specimen, at least ten blocks of lung tissue taken macroscopically had abnormal appearing lungs, of which the upper (four blocks), middle (two blocks) and lower lobes (four blocks) were available. Vascular resection margin and bronchial resection margin were sampled. The pathological specimens were sectioned and stained with hematoxylin and eosin (HE), elastic Verhoeff Van Gieson stain for vessel identification, an masson trichrom for fibrosis, Prussian blue for hemosiderosis . Pulmonary vessels were analyzed in all sections. The following modifications were investigated: occlusive intimal fibroelastosis, smooth muscle proliferation, medial hypertrophy, intimal cellular or fibrous thickening, hemosiderosis, plexiform lesion, angiomatoid lesion, atherosclerosis, venopathy, capillary duplication and arteriovenous malformation. Vascular abnormalities were reported as present or absent. Atherosclerotic lesions were evaluated in the vascular resection margin. When calcification was observed with atheromatous plaque consisting of foamed macrophage and connective tissue at the vascular surgery border, it was evaluated as an atherosclerotic lesion [5].
Areas consisting of dilated vessels with different diameters and wall thickness were recorded as arterio-venous malformations (6). Diffuse intimal fibrosis or chronic perivenous inflammation and occlusion findings in the veins were evaluated as venopathy. Verhoeffs elastic stain was used to separate the veins from the arteries [4]. Increased number of congested alveolar capillaries in interstitium in the areas where the lung preserves its structure was evaluated as capillary duplication [2] Occlusive intimal fibroelastosis, smooth muscle proliferation, medial hypertrophy, intimal cellular or fibrous thickening, hemosiderosis, plexiform lesion and angiomatoid lesion investigated in the parenchyma were the patterns used for the histological grading of hypertensive pulmonary arterial hypertension [7, 8, 9].

Pulmonary hemodynamic assessment

Pulmonary artery pressure is normally lower than systemic blood pressure. Normal mean pulmonary artery pressure is 10-15 mmHg, and systolic pulmonary artery pressure is 18-25 mmHg, at rest. However, systolic pulmonary artery pressure that is higher than 40 mmHg is referred to as pulmonary hypertension. Pulmonary hypertension is used to describe an increase in pulmonary artery pressure. Both systolic and mean pulmonary artery pressures were defined by either echocardiography (ECHO) or pulmonary catheterization [10].

Statistical analysis

The pathological data were expressed using statistical analyses, which were conducted using the SPSS statistical software package (version 17.0, SPSS, Chicago, Illinois, United States). The t-test and one-way ANOVA test (Scheffe test and Tamhane test) were used to analyze the potential differences between study groups. In cases where a difference was detected between the groups, the Levene test was used to check the differences between the variances and to identify which group was the source of the difference. The variances were not equal when p values were < 0.05 based on the Levene test; variances were considered equal when p values were > 0.05 based on the Levene test. Based on t-tests and one-way ANOVA test (Scheffe test and Tamhane test), p values of < 0.05 were considered statistically significant [11].

Results

Characteristics of the patients

A total of 57 cases were included in the study between 2013 and 2019. Bilateral sequential lung transplantation was performed in 51 (89.5%) cases and single lung transplantation was performed in six (10.5%) cases. The youngest of 48 male and nine female patients was 19 years old and the oldest was 65 years old. The cases (n = 57) were divided into three groups as emphysematous (n = 20), fibrotic (n = 29) and suppurative (n = 8; Table I). The fibrotic group consisted of idiopathic pulmonary fibrosis (IPF), Non-specific interstitial pneumonia (NSIP), silicosis, Langerhans’ cell histiocytosis, alveolar lipoproteinosis, bronchiolitis obliterans (BO), adult respiratory distress syndrome, graft versus host disease and lymphanjioleiomyomatosis. The youngest patient in the fibrotic group was 25 and the oldest was 61 years old. Twenty-four were men and five were women. The most frequently observed patients in the fibrotic group were those diagnosed with IPF (n = 14). The emphysematous group consisted of COPD (n = 19) and α 1-antitrypsin deficiency (n = 1). The age range of patients ranged from 28 to 65, with 19 male patients and one female patient.
The suppurative group consisted of patients with bronchiectasis (n = 7) and cystic fibrosis (n = 1). Two patients in the bronchiectasis group were followed by Kartagener’s Syndrome. Five were male and three were female. The youngest was 19 and the oldest was 59 years old. The relationship between pulmonary hypertension and pathological vascular changes Pathological vascular alterations in explanted lung with or without pulmonary hypertension were medial hypertrophy (80.71%), intimal cellular or fibrous thickening (80.7%), arteriosclerosis (77.19%), smooth muscle proliferation (54.3%) and arteriovenous malformation (50.3%) (Fig. 1). Hemosiderosis (12.5%), plexiform lesion (14%) and venopathy (21%) were less frequent pathological vascular alterations (Fig. 2). The fibrotic, emphysematous and suppurative groups were compared in terms of the frequency of the histopathological parameters investigated (Table II). Occlusive intimal fibroelastosis and smooth muscle proliferation were more common in the fibrotic group than in the emphysematous group (p < 0.05, p = 0.013, p = 0.012). Intimal cellular or fibrous thickening was more common in the emphysematous group than in the suppurative group (p < 0.05, p = 0.014). Plexiform lesions were more common in the fibrotic group than in the emphysematous group (p < 0.05, p = 0.034). Arteriovenous malformations were more common in the emphysematous and suppurative groups than in the fibrotic group (p < 0.05, p = 0.01, p = 0.01). There was no difference between the groups in terms of the frequency of other histopathological parameters.
Before transplantation, systolic and mean pulmonary artery pressures were detected by ECHO or pulmonary artery catheterization. Pulmonary hypertension was defined as a mean pulmonary artery pressure > 25 mmHg or systolic pulmonary artery pressure > 40 mmHg. It was observed that there was no statistically significant difference between patients with normal pulmonary artery pressure and those with pulmonary hypertension in terms of histopathological parameters other than capillary duplication (Fig. 3). Capillary duplication is more common and statistically significant in patients with pulmonary hypertension than in those without pulmonary hypertension (13 [22.81%] vs. 4 [7.02%], p < 0.05, p = 0.038; Table III).

Discussion

The main function of the lung is to change carbon dioxide in the blood to oxygen. The pulmonary vascular system is specialized to perform this function. The pulmonary vascular structure receives the entire cardiac output. Pulmonary circulation is low-pressure to distribute cardiac output to all parts of the lung and is 10 mmHg at rest. Structural changes in explant lungs in patients undergoing lung transplantation disrupt carbon dioxide and oxygen exchange. Pulmonary parenchymal loss leads to vascular remodeling [12]. Not only primary disease but also vascular changes are observed in explant materials. The morphological features of this remodeling determines the clinical situation. The most important finding of vascular changes is pulmonary hypertension. Parenchymal diseases of the lung are one of the most important causes of pulmonary hypertension. However, pulmonary hypertension does not develop clinically in every patient, even in the end-stage. In our study, we observed medial hypertrophy in the artery walls with intimal cellular or fibrous thickening, which is a symptom of pulmonary arterial hypertension, even in patients with normal pulmonary blood pressure. These two vascular changes are the two most common findings in patients with PAH in many studies [2, 3]. Although the pathogenesis of PAH is not fully understood, it suggests that intimal cellular or fibrous thickening and medial hypertrophy in the artery walls do not constitute PAH alone. This may be a common sign of vascular remodeling or loss of alveolar function independent of etiology. The most important difference between primary PAH and secondary PAH is that plexiform and angiomatoid lesions are less frequent in secondary PAH [13].
In our cases, plexiform lesions were observed at a rate of 14.03%. In our study, we more frequently observed plexiform lesions in the fibrotic group than in the emphysematous group. This may be due to the fact that vascular remodeling induced by fibrosis in patients forming the fibrotic group uses mechanisms similar to those of primary PAH. Colombat et al. detected different types of vascular changes in areas where patients with IPF retain their normal structure. Occlusion of pulmonary venules, alveolar capillary multiplication and muscular hyperplasia in the arteries are the most common vascular lesions [2]. In our study, although there was no difference between the groups, medial hypertrophy was common in the fibrotic group.
Fartoukh and colleagues have observed intimal fibrosis and medial hypertrophy in the arteries in patients with Langerhans cell histiocytosis. Venular obliteration, hemosiderosis and capillary dilation were observed in one-third of the cases. Similar changes were also observed in the unaffected areas of the parenchyma in half of the cases. In the same study, intimal fibrosis and medial hypertrophy in the arteries were observed in patients with pulmonary hypertension, COPD and IPF. They detected veno-occulusive-like disease characterized by venular obliteration, hemosiderosis and capillary dilation only in patients with Langerhans cell histiocytosis [3]. We detected only 10.53% of our hemosiderosis cases. Although it was observed most frequently in the fibrotic group, we did not see a statistically significant difference between the groups. Smooth muscle hyperplasia in the parenchyma is observed in patients with severe pulmonary hypertension [14, 15]. However, although none of our cases had severe PAH, we detected smooth muscle hyperplasia in 54.38% of the cases. We think that in patients with secondary PAH, parenchymal smooth muscle hyperplasia is not directly proportional to the severity of blood pressure and is due to parenchymal changes caused by primary disease.
Arteriosclerosis is the focal thickening of the intima that causes serious diseases such as heart attack and cerebrovascular diseases. Studies have shown that the thickness of the internal elastic laminate of the arteries affects arterial involvement. The internal elastic lamina of the peripheral arteries is thinner and not dense. Therefore it is more involved than the cerebral arteries [16]. In our study, we observed arteriosclerosis findings characterized by atheroma plaques and calcification at the vascular surgical margin in 77.19% of the explant lungs. Studies have shown that coronary artery disease is higher in transplant candidates with fibrotic lung disease than in patients with emphysema. Therefore the inflammatory process in end-stage lung diseases is not only limited to the lungs but is a systemic process [17, 18]. This situation explains the frequency of histopathological findings of arteriosclerosis in our cases.
It is the third group of PAH that is secondary to lung diseases and hypoxia, according to the Evian classification. Hypoxia is the primary cause. Small pulmonary artery vasoconstriction underlies the pathogenesis. The prognosis depends on the severity of the pulmonary disease rather than the hemodynamic disorder. Histopathologically, medial hypertrophy and smooth muscle proliferation spread to the periphery in small arteries. Pulmonary capillary hemangiomatosis, on the other hand, is a proliferation of capillaries in the interstitium that causes pulmonary hypertension [19]. Studies have shown that interstitial capillary proliferation develops in the lungs of patients who develop PAH on the fibrotic ground associated with systemic sclerosis [20]. In our study, a statistically significant difference was observed between patients with normal pulmonary artery pressure and those with PAH in terms of interstitial capillary duplication. Interstitial capillary duplication is histologically similar to capillary hemangiomatosis. In our study, we found that secondary hypertension is an important histopathological finding in end-stage lung diseases.
Although pulmonary hypertension is a disease of the arteries, venous diseases are also an important entity in this group. Both arterial and venous remodeling are observed in all forms of pulmonary hypertension, including interstitial lung diseases. Saggar et al. detected venopathy consisting of obliteration, perivenous mononuclear cell infiltration and secondary capillary congestion in pulmonary veins in bronchiolitis obliterans patients with pulmonary hypertension [4]. Normal pulmonary veins do not have a double elastic layer and contain a thin muscular layer. When remodeling, they cannot be distinguished from the artery as “arterialized”. Therefore it is difficult to examine venous remodeling without certain molecular markers [21]. In our study, we examined the interlobular septa and the subpleural areas by applying verhoff elestica paint, in which the veins can be observed more easily in terms of venopathy. We detected venopathy most frequently in the emphysematous group. However, we could not detect its relationship with pulmonary hypertension. Stacher et al. did not find a relationship between venous remodeling and arterial media and intima thickness in patients with pulmonary arterial hypertension and scleroderma [22]. The remodeling of pulmonary veins and venules is at the forefront, especially in patients with PAH due to connective tissue diseases. These patients are therefore resistant to PAH treatment [23]. Genetic studies on mRNA and protein levels in lung explants have shown that pulmonary venous occlusive disease shares more features with IPF than PAH [24].
In our study, we detected arteriovenous malformation in 50.8% of all cases in all three groups, mostly in the emphysematous group. The most common cause of pulmonary arteriovenous malformations is hereditary hemorrhagic telangiectasia [25]. Acquired arteriovenous malformation; infections such as hepatic cirrhosis, mitral stenosis, actinomycosis, cystosomiasis, tuberculosis, hydatid cyst develop as a result of metastatic carcinoma or trauma. Neovascularization in the area of inflammation is the main mechanism for the development of arteriovenous malformation [26]. Prolonged inflammation is also included in the etiology of PAH. Especially perivascular lymphoid infiltrations consisting of lymphocytes have been shown to correlate with pulmonary vascular remodeling parameters and hemodynamic parameters in PAH. The interaction between specialized cells and soluble factors creates an inflammatory response to infection, trauma and autoimmunity [22, 27, 28]. Our study is the first study to emphasize that arteriovenous malformation in end-stage lung diseases is a sign of vascular remodeling.
Vascular remodeling is a complex process playing a role in cellular adaptation mechanisms and numerous molecules in end-stage lung diseases. Changes in the TGFß signal pathway, especially mutations in the TGF-β receptor superfamily, are the underlying cause of PAH [29]. Growth factors are potent mitogens and chemoattractants for vascular cells such as smooth muscle cells, fibroblasts and endothelial cells. The binding of growth factors to tyrosine kinase receptors initiates major signaling pathways, causing cell proliferation, migration and apoptosis resistance [30]. Genetic factors create PAH through exaggerated cellular response, chronic inflammatory stimuli, exacerbation of metabolic changes, and accumulation of DNA damage. The metabolic flexibility and changes in cell activities play an important role in the pathogenesis of PAH [21]. Myofibroblasts can occur with epithelial mesenchymal passage from epithelial cells. At the same time, TGF-β stimulation activates fibroblasts, causing myofibroblast formation. Studies have shown that TGF-β also plays an important role in idiopathic pulmonary fibrosis [31]. TGF-β leads to fibrosis with tenascin-C secretion and promotes repair. However, both processes are disrupted by oxidative damage [32]. Similar to the role of TGF-β in pulmonary fibrosis, TGF-ß provides airway remodeling in patients with COPD [33]. All these studies reveal that the processes that cause disruptions in the normal lung structure also cause vascular remodeling. However, this does not fully explain the differences in vascular patterns.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting disease (COVID-19) has caused a worldwide pandemic that causes mortality and morbidity. Most COVID-19 patients have mild symptoms or asymptomatic. However, acute respiratory distress syndrome (ARDS) develops in 10% of the cases. Mortality is 60% in this group. Lungs being the main target organ in COVID-19, metabolic and hematological changes are the most important causes of mortality. Pathological changes are caused by an excessive response of immune cells such as macrophages and mast cells. Mast cells are producers of histamine. They increase the production of IL-1. IL-1 is a pleiotropic cytokine that is active in inflammation and immunity [34]. IL-1 causes hypotension. It does this by causing a decrease in systemic blood pressure, a decrease in vascular resistance, an increase in heart rate, and leukocyte aggregation. IL-1 induces thromboxane B2 (TxB2) releases in activated neutrophils and macrophages. An increase in thromboxane can induce leukocyte aggregation and systemic inflammation, which would account for bronchopneumonia, microtrombi, ischemic lesions, pulmonary emboli, or pulmonary infarct. Therefore, drugs that reduce IL-1 are recommended in the treatment of COVID-19 [35, 36].
Immunological mechanisms that play a role in pulmonary remodeling in the COVID-19 will also be guiding in terms of the mechanisms and treatment principles of vascular changes in end-stage lung diseases. Vascular remodeling patterns are important findings that affect the clinical situation, treatment and prognosis in end-stage lung diseases. Although medial hypertrophy and intimal thickness were seen in pulmonary hypertension, they can be observed in end-stage pulmonary diseases without pulmonary hypertension. Interstitial capillary duplication is histologically similar to capillary hemangiomatosis. In our study, we found that capillary duplication is common histopathological finding in explanted lung with secondary pulmonary hypertension. Also, arteriosclerosis and arteriovenous malformation were other pulmonary vascular alterations that were detected in end-stage pulmonary diseases.
The authors declare no conflict of interest.

References

1. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62 (25 Suppl):
2. D109-16.
3. Colombat M, Mal H, Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 3: 60-65.
4. Fartoukh M, Humbert M, Capron F, et al. Severe Pulmonary Hypertension in Histiocytosis X. Am J Respir Crit Care Med 2000; 161: 216-223.
5. Saggar R, Ross D J, Saggar R, et al. Pulmonary Hypertension Associated With Lung Transplantation Obliterative Bronchiolitis and Vascular Remodeling of the Allograft. Am J Transplant 2008; 8: 1921-1930.
6. Mitchell RN. Blood vessels. In: Kumar V, Abbas AK, Aster JC.
7. Robbins Basic Pathology. 10th ed. Philadelphia Elsevier 2018.
8. Development of the lungs; perinatal and developmental lung disease. In: Corrin B. Pathology of the lung. 3rd Edition Edinburg: Elsevier; 77.
9. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18:
10. 533-547.
11. Wagenvoort CA. Grading of pulmonary hypertension. Am
12. J Cardiol 1987; 60: 943.
13. Helmut Popper Vascular Lung Diseases. Pathology of Lung Disease 2016; 24: 251-273.
14. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
15. Yazicioglu Y, Erdogan S. SPSS Uygulamalı Bilimsel Araştırma Yöntemleri, 3rd Edition 2011; 277-291.
16. Tuder RM. Pulmonary Vascular Remodeling in Pulmonary Hypertension. Cell Tissue Res 2017; 367: 643-649.
17. Young RH, Mark GJ. Pulmonary Vascular Changes in Scleroderma. Am J Med 1978; 64: 998-1004.
18. Kay JM, Kahana LM, Rihal C. Diffuse smooth muscle proliferation of the lungs with severe pulmonary hypertension. Hum Pathol 1996; 27: 969-974.
19. Rydell-Törmänen K, Risse PA, Kanabar V, et al. Smooth muscle in tissue remodeling and hyper-reactivity: airways and arteries. Pulm Pharmacol Ther 2013; 26: 13-23.
20. Qin G , Wang L, Hua Y, et al. Comparative Morphology of the Internal Elastic Lamina of Cerebral and Peripheral Arteries. Int J Clin Exp Pathol 2020; 13: 764-770.
21. Izbicki G, Ben-Dor I, Shitrit D, et al. The Prevalence of Coronary Artery Disease in End-Stage Pulmonary Disease: Is Pulmonary Fibrosis a Risk Factor? Respir Med 2009; 103: 1346-1349.
22. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 2004; 164: 551-556.
23. Foshat M, Boroumand N. The Evolving Classification of Pulmonary Hypertension Arch Pathol Lab Med 2017; 141: 696-703.
24. Seki A, Anklesaria Z, Saggar R, et al. Capillary Proliferation in Systemic-Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. ACR Open Rheumatol 2019; 1: 26-36.
25. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D4-12.
26. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261-272.
27. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902.
28. Neubert L, Borchert P, Stark H, et al. Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. Am J Pathol 2020; 190: 1382-1396.
29. Salibe-Filho W, Piloto BM, Oliveira EP, et al. Pulmonary arteriovenous malformations: diagnostic and treatment characteristics. J Bras Pneumol 2019; 45: e20180137.
30. Gezer S, Turut H, Oz G, Demirag F, Tastepe I. Acquired pulmonary arteriovenous malformation secondary to hydatid cyst operation. Thorac Cardiovasc Surg 2007; 55: 462-463.
31. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998; 132: 16-24.
32. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.
33. De la Cuesta F, Passalacqua I, Rodor J, et al. Extracellular Vesicle Cross-Talk Between Pulmonary Artery Smooth Muscle Cells and Endothelium During Excessive TGF-β Signalling: Implications for PAH Vascular Remodelling Cell Commun Signal 2019; 17: 143.
34. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of Disease: Pulmonary Arterial Hypertension Nat Rev Cardiol 2011; 8: 443-455.
35. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC, Ten Dijke P. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Int J Mol Sci 2017; 18: 2157.
36. Fitch PM, Howie SEM, Wallace WAH. Oxidative damage and TGF-β differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease. Int J Exp Pathol 2011; 92: 8-17.
37. Aschner Y, Downey GP. Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease. Am J Respir Cell Mol Biol 2016; 54: 647-655.
38. Conti P , Caraffa A, Tetè G, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents 2020; 34: 1629-1632.
39. Conti P, Gallenga CE, Tetè G, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020; 34: 333-338.
40. Conti P, Caraffa A, Gallenga CE, et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020; 34: 1623-1627.
Copyright: © 2021 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe